Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Anthem Biosciences Limited

NSE: ANTHEMBiotechnology

Share price

₹872.55

-1.63% close of 8 Oct 2026

Market cap ₹48,863 CrP/E 82.4

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

62

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹48,863 Cr

P/E ratio

82.4

P/B ratio

16.1

ROCE

30.4%

ROE

22.3%

Dividend yield

0.2%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹957.8052-week low ₹587.85

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

It grew 5.7% a year against a sector median of 13.1% — 7.4 percentage points slower.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 3.9 times its growth rate, on earnings growth of 21%.

Profit growthPrice per ₹1 profitPer 1% growth
Anthem Biosciences Limited — this one21%/yr82.4×₹3.9
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Apollo Hospitals32%/yr52.5×₹1.6

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies across the whole Healthcare sector, it ranks 17 of 185 on returns, 141 of 176 on growth, 8 of 186 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 30.4% on capital, ahead of 91% of companies across its whole sector. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1894 crore of cash from the business, spent ₹982 crore on plant and equipment, and returned ₹8 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 7 years, about 91 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 75 days for its cash to waiting 92 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q4 FY26

What the last results showed. Whether management kept its word is in Pro.

Sales grew 26.44% to 610.943 crore.

Announced 21 Sep 2026 · Consolidated · Audited

Revenue

₹611 Cr

Revenue vs last year

+26.4%

Revenue vs last quarter

+44.4%

Net profit

₹190 Cr

Profit vs last year

+128.6%

Profit vs last quarter

+104.0%

Net margin

31.1%

EPS

₹3.38

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹48,863 Cr
Prev close
₹872.55
52w High
₹978
52w Low
₹579
Enterprise value
₹48,980 Cr
Beta
0.7
Price CAGR 1y
14.0%
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
17.3%
PEG ratio
3.9
P/E ratio
82.4
P/B ratio
16.1
EV / EBITDA
59.1
Industry P/E
40.5
ROCE
30.4%
ROCE 5y average
32.2%
ROE
22.3%
Debt / Equity
0.0
Interest coverage
118.7
Dividend yield
0.2%
ROE 3y average
21.0%
ROE last year
22.0%

Annual P&L

Annual revenue
₹2,124 Cr
Annual profit
₹592 Cr
Operating margin
39.0%
Net profit margin
27.9%
EBITDA margin
39.3%
Sales growth 3y
26.2%
Sales growth 5y
14.0%
Profit growth 3y
21.0%
Profit growth 5y
17.0%
EPS
₹10.5
Sales growth TTM
-2.0%
Profit growth TTM
18.0%
Dividend payout
19.0%

Quarter P&L

Sales latest quarter
₹418 Cr
Profit latest quarter
₹120 Cr
YoY quarterly sales growth
-22.6%
YoY quarterly profit growth
-11.8%
OPM latest quarter
36.0%

Balance Sheet

Book Value
₹54.3
Face Value
₹2.0
Total debt
₹54 Cr
Total cash
₹275 Cr
Borrowings
₹54 Cr
Reserves / Equity
26.2

Cash Flow

Operating cash flow
₹844 Cr
Free cash flow
₹637 Cr
FCF yield
1.3%
Net cash flow
₹103 Cr

Shareholding

Promoter holding
71.4%
FII holding
2.6%
DII holding
13.5%
Public holding
12.5%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Anthem Bioscienc887.0584.350,0160.23119.9-11.7418.2-22.630.4
Advanced Enzyme270.0519.23,0191.9838.6-7.1189.82.114.0
CCME Global35.601610.00-0.3-116.70.0-2.9
Vivo Bio Tech15.10330.000.2-85.814.314.27.7
Shree Ganesh Bio0.47190.00-0.6-272.71.43.61.3
Genomic Valley32.24984.7100.000.0-50.00.0-55.61.0
Median270.0551.73,0190.2338.6-11.7189.8-10.214.0

Competes with: Advanced Enzyme Technologies Limited, Vivo Bio Tech Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales339525498483540550423611418
Expenses218330338288349332266344268
Material Cost162201185165149
Change in Inventories6922-4250-2.36
Purchases of Stock-in-Trade00000
Employee Cost7268707279
Other Expenses4641535643
Operating Profit121195160195191218157267151
OPM %363732403540374436
Other Income19282414234885225
Exceptional items (within Other Income)00-250.980
Interest443123021
Depreciation192020302634354030
Profit before tax118200161178186230130278145
Tax %301923542724293217
Net Profit821621248313617393190120
EPS in Rs1.472.902.221.482.423.091.653.382.13
Diluted EPS in Rs2.423.061.643.342.11

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6331,1031,2311,0571,4191,8452,1242,002
Expenses4516956666269141,1731,2901,209
Material Cost714
Change in Inventories99
Purchases of Stock-in-Trade0
Employee Cost283
Other Expenses196
Operating Profit182408565431506672834793
OPM %2937464136363940
Other Income2137491396385131133
Exceptional items (within Other Income)-24
Interest201710910116.896
Depreciation626258648289134138
Profit before tax121366546497477657824783
Tax %23262623233128
Net Profit93271406385367451592576
EPS in Rs1113204626.756.578.071110
Diluted EPS in Rs10
Dividend Payout %00000019

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
14%
3 years
26%
TTM
-2%

Compounded profit growth

10 years
—
5 years
17%
3 years
21%
TTM
18%

Stock price CAGR

10 years
—
5 years
—
3 years
—
1 year
14%

Return on equity

10 years
—
5 years
23%
3 years
21%
Last year
22%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital889114112112112
Reserves4136931,3461,6271,8132,2982,930
Borrowings1591003512623911354
Other Liabilities207232228148235284333
Total Liabilities7871,0341,6192,0142,3982,8083,429
Fixed Assets306361329449483705783
CWIP5019154164345297264
Investments992092734994724331,007
Other Assets3334458639021,0991,3731,374
Total Assets7871,0341,6192,0142,3982,8083,429

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity166278333306140271844
Cash from Investing Activity-109-196-205-376-221-147-702
Cash from Financing Activity-48-6318164-77-136-40
Net Cash Flow918308-6-158-12103
Free Cash Flow119159307112-15612637

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6184979512689101
Inventory Days186295213912916756
Days Payable87505077615434
Cash Conversion Cycle1606399156193202124
Working Capital Days20277511212813492
ROCE %555128242830

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2025Dec 2025Mar 2026Jun 2026
Promoters75757571
FIIs1.661.371.282.57
DIIs7.217.601213
Public16161213
No. of Shareholders2,17,6811,99,4921,80,2201,73,273

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +12.9% (₹772.75 → ₹872.55)Brick size ₹28.20 (fixed)Bricks 23
₹600₹700₹800₹873Nov '25Feb '26May '26
Price moved up one brickPrice moved down one brickLast close ₹872.55 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

93,07,625inr

2026-03-31

News

News and filings about Anthem Biosciences Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Domestic raw materials and excipients
  • Key raw materials, intermediates, catalysts, reagents and solvents
  • Lab chemicals and consumables
  • PRC-sourced raw materials and intermediates

Buys from

Sells to

  • DavosPharma / Davos Chemical Corporation · US business-development / customer channel for CRDMO services
  • Emerging biotech innovators (NCE/NBE programs) · drug discovery, development and custom synthesis

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Biotechnology
Classification
Healthcare › Biotechnology
ISIN
INE0CZ201020

Business segments

  • CRDMO · 84%
  • Speciality Ingredients · 17%

Plants

  • Anthem Biosciences Bommasandra Unit
  • Anthem Biosciences Harohalli Units

News impact

Big market events that reach Anthem Biosciences Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

25 Jun 2026unspecified₹2

Splits, bonuses & buybacks

  • daily-prices repair: 2 rows from NSE's archive (replace 0, delete 1, insert 1), 2026-01-15..2026-02-01 (docs/flat_day_repair.md)1× · 15 Jan 2026

Bulk & block deals

DateWhoBought / soldSharesPrice
18 Jun 2026ARUNA GANESHSELL1,71,14,604₹744.80

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
21 Sep 2026Viridity Tone LLP · Designated PersonSELL9,00,00082.67

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.